TMCI at a glance
TREACE MEDICAL CONCEPTS, INC. (TMCI, SEC CIK 1630627) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 7, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TREACE MEDICAL CONCEPTS, INC. (TMCI) reported revenue of $212.7 million (up 1.6% from FY2024) and a net loss of $59.0 million. Diluted EPS was -$0.93.
- As of June 30, 2026, 18 institutional investment managers tracked by SignalX reported holding TREACE MEDICAL CONCEPTS, INC. (TMCI) shares worth $47.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Treace John T. on August 24, 2026 of 11,000 shares at $4.34 per share.
- In the last 90 days, TMCI insiders reported 3 open-market purchases ($247K) and 0 open-market sales ($0) on Form 4, a net purchase of $247K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $212.7M
- +1.6% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$247K
- 13F holders
- 18 funds
- $47.7M · −5 vs prior quarter
- Latest 8-K
- Aug 7, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
- New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
- Strategic shift: Addressing surgeon shift to minimally invasive bunion surgery with lower-priced new product lines; growing stocking distributor sales (from $0 to $13M in 2025)
- Quantitative highlights: Active surgeons increased 6% to 3,337; direct sales force generated 80% of 2025 revenue; marketable securities $37.7M; legal expenses up $5.4M due to patent infringement lawsuits
- Noteworthy fact: Filed multiple patent infringement lawsuits in 2024-2025 against major competitors Stryker and Zimmer Biomet over Lapiplasty 3D technology
Management Discussion & Analysis
- Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
- Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
- Best segment: not segmented; gross profit stable at $169.8M vs $168.3M; no segment-level details; worst metric: net loss deepening
- Operating cash flow use $16.0M in 2025 vs $37.2M in 2024; investing cash inflow $13.3M in 2025 driven by sales/maturities of securities; financing cash inflow $2.1M in 2025 primarily from new term loan net proceeds ($59.3M) and repayments of prior loans ($56.3M)
- Management expects existing cash, securities ($10.7M + $37.7M), and credit facilities sufficient for 12+ months; potential need to raise additional capital to support growth and operational needs; risks include market acceptance, competition, supply chain, economic factors, and litigation impacts
AI summary of the TMCI 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $45.4M, down 4.2% YoY from $47.4M, including $3.1M lower stocking-distributor sales
- Gross margin 78.5% vs 79.7% YoY
- Operating loss $15.0M vs $17.0M YoY; net loss $15.9M vs $17.4M
- Cash and equivalents $12.6M plus marketable securities $33.0M at June 30, 2026
- Macro pressures, competition, lower-priced minimally invasive kits, and declining Lapiplasty sales expected to weigh on demand
Risk Factors
- No Risk Factors section provided in the filing excerpt
- Newly amended bylaws addressing SEC universal proxy Rule 14a-19 compliance
- Enhanced stockholder nomination disclosures and notice requirements
- Stockholder proxy solicitations now require non-white proxy cards
- 11,547 shares withheld at $2.23 per share for employee tax obligations
AI summary of the TMCI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 7, 2026 and furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $45.4M, down 4% YoY, while operating expenses fell 8% to $50.6M
- Net loss improved to $15.9M from $17.4M; adjusted EBITDA loss narrowed to $3.5M from $3.6M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Three Class II director nominees elected to terms expiring at the 2029 annual meeting
- Executive compensation approved by advisory vote, with 32,785,505 votes for and 1,724,383 against
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains the financial results and management commentary
AI summaries of TMCI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TMCI
Don't miss the next TMCI filing
- Alerts as it files. A push when TMCI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TMCI, by share count.
- Ask anything. An AI agent that reads every TMCI filing and answers with sources.
TMCI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Elder Scot Michael | F | Sep 30, 2026 | 25,457 | - |
| Treace John T. | Buy | Aug 24, 2026 | 11,000 | $4.34 |
| Treace John T. | Buy | Aug 21, 2026 | 5,000 | $4.35 |
| Treace John T. | Buy | Aug 20, 2026 | 39,944 | $4.44 |
| Scanlan Sean F. | F | Aug 9, 2026 | 9,814 | - |
| Elder Scot Michael | F | Aug 9, 2026 | 16,253 | - |
| Hair Mark | F | Aug 9, 2026 | 37,102 | - |
| Treace John T. | Buy | Jun 11, 2026 | 9,891 | $4.04 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $209.4M | $212.7M |
| Gross Profit | - | $168.3M | $169.8M |
| Operating Income | - | -$55.7M | -$54.2M |
| Net Income | - | -$55.7M | -$59.0M |
| Gross Margin | - | 80.4% | 79.8% |
| Op. Margin | - | -26.6% | -25.5% |
| Net Margin | - | -26.6% | -27.7% |
| Balance Sheet | |||
| Total Assets | $251.9M | $217.1M | $190.6M |
| Equity | - | $112.9M | $87.3M |
| ROE | - | -49.4% | -67.6% |
| Per Share | |||
| EPS | - | $-0.90 | $-0.93 |
| Cash Flow | |||
| Operating CF | - | -$37.2M | -$16.0M |
| CapEx | $11.5M | $11.6M | $13.5M |
Source: XBRL data in TREACE MEDICAL CONCEPTS, INC. (TMCI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TMCI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 18 | $47.7M |
| Q1 2026 | 23 | $21.3M |
| Q4 2025 | 20 | $32.4M |
| Q3 2025 | 22 | $102.9M |
| Q2 2025 | 24 | $83.5M |
| Q1 2025 | 22 | $85.6M |
| Q4 2024 | 17 | $48.9M |
| Q3 2024 | 14 | $22.9M |
- Vanguard Capital Management LLC+567.0K (+39%)
- AQR Capital Management+435.8K (+41%)
- Goldman Sachs Group+104.4K (+27%)
- Morgan Stanley+100.3K (+46%)
- Bank of America Corp+90.8K (+3%)
- BlackRock−1.96M (-59%)
- State Street Corp−1.00M (-81%)
- Renaissance Technologies LLC−474.6K (-91%)
- Millennium Management−409.5K (-36%)
- Citadel Advisors LLC−308.6K (-37%)
- BNY Mellon−121.0K
- T. Rowe Price Group−25.6K
- Invesco Ltd−25.0K
- Wells Fargo & Co−17.5K
- Citigroup−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 160 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TMCI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| SC 13G | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 20, 2026 | - | - | - |
| 8-K | Apr 9, 2026 | - | Analysis | - |
| 4 | Mar 11, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TMCI SEC filings: frequently asked questions
Are TMCI insiders buying or selling?
In the last 90 days, TREACE MEDICAL CONCEPTS, INC. (TMCI) officers, directors and 10% owners reported 3 open-market purchases worth $246,654 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TMCI stock?
As of June 30, 2026, the largest TREACE MEDICAL CONCEPTS, INC. (TMCI) holders among the 13F filers tracked by SignalX were Bank of America Corp ($13.2 million), Vanguard Capital Management LLC ($8.1 million), AQR Capital Management ($6.0 million), BlackRock ($5.5 million), Millennium Management ($2.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TMCI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TREACE MEDICAL CONCEPTS, INC. (TMCI) reported revenue of $212.7 million (up 1.6% from FY2024) and a net loss of $59.0 million. Diluted EPS was -$0.93. The figures come from the XBRL data in the 10-K.
What did TMCI report in its latest 8-K?
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed an 8-K on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest TMCI SEC filings?
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 7, 2026 and a Form 4 insider filing on October 2, 2026.
What is TMCI's SEC CIK number?
TREACE MEDICAL CONCEPTS, INC. (TMCI)'s SEC Central Index Key (CIK) is 1630627. EDGAR lists every TMCI filing under that number.
Ask anything about TMCI
The research agent reads TMCI's filings, financials, insider trades and 13F holders, then answers with sources.